These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23104210)

  • 1. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
    J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
    Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
    J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Taylor KL; Shelby R; Gelmann E; McGuire C
    J Natl Cancer Inst; 2004 Jul; 96(14):1083-94. PubMed ID: 15265970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
    Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
    Pierre-Victor D; Pinsky PF
    JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Loomans-Kropp HA; Pinsky P; Cao Y; Chan AT; Umar A
    JAMA Netw Open; 2019 Dec; 2(12):e1916729. PubMed ID: 31800071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of lung cancer screening results on smoking cessation.
    Tammemägi MC; Berg CD; Riley TL; Cunningham CR; Taylor KL
    J Natl Cancer Inst; 2014 Jun; 106(6):dju084. PubMed ID: 24872540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary fiber intake and the risk of bladder cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort.
    Luo J; Xu X
    Carcinogenesis; 2020 Jun; 41(4):478-482. PubMed ID: 31872237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.
    Zhu CS; Pinsky PF; Kramer BS; Prorok PC; Purdue MP; Berg CD; Gohagan JK
    J Natl Cancer Inst; 2013 Nov; 105(22):1684-93. PubMed ID: 24115361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.
    Kirsh VA; Hayes RB; Mayne ST; Chatterjee N; Subar AF; Dixon LB; Albanes D; Andriole GL; Urban DA; Peters U;
    J Natl Cancer Inst; 2006 Feb; 98(4):245-54. PubMed ID: 16478743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
    Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
    PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.
    Pinsky PF; Kramer BS
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26483244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Kitahara CM; Berndt SI; de González AB; Coleman HG; Schoen RE; Hayes RB; Huang WY
    J Clin Oncol; 2013 Jul; 31(19):2450-9. PubMed ID: 23715565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    Katki HA; Prorok PC; Castle PE; Minasian LM; Pinsky PF
    J Natl Cancer Inst; 2024 Aug; 116(8):1280-1287. PubMed ID: 38603624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.
    Tammemagi MC; Freedman MT; Pinsky PF; Oken MM; Hu P; Riley TL; Ragard LR; Berg CD; Prorok PC
    J Thorac Oncol; 2009 Jun; 4(6):710-21. PubMed ID: 19404219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Pinsky PF; Kramer BS; Reding D; Buys S;
    Am J Epidemiol; 2003 May; 157(9):792-9. PubMed ID: 12727673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Miller AB; Yurgalevitch S; Weissfeld JL;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.